Research progress of liquid biopsy for predicting recurrence in patients with hepatocellular carcinoma after liver transplantation

doi:10.3877/cma.j.issn.1674-3903.2021.03.014

Abstract

Abstract:

Liver transplantation is an effective method for the treatment of primary liver cancer. However, liver cancer recurrence after liver transplantation greatly affects survival of patients. The main goals of prevention and treatment of liver cancer recurrence are to explore recurrence markers after liver transplantation, screen high-risk recurrence groups and provide early warning signs. At present, studies on recurrence factors of liver transplantation mainly focus on two aspects: preoperative and postoperative clinical factors which have many detailed research reports; predictability of recurrence based on biomarkers. With the development of biotechnology, predictability of biomarkers has become hotspot on liver cancer recurrence after liver transplantation. Therefore, the non-invasive test based on body fluid samples, named liquid biopsy, is a promising marker and has been widely concerned in the prediction of recurrence after liver transplantation. Our review summarizes the recent studies of liquid biopsy on the prediction of liver cancer recurrence after liver transplantation.

Key words: Liquid biopsy, Hepatocellular carcinoma, Liver transplantation, Recurrence prediction

Ruitao Wang. Research progress of liquid biopsy for predicting recurrence in patients with hepatocellular carcinoma after liver transplantation[J]. Chinese Journal of Transplantation(Electronic Edition), 2021, 15(03): 189-192.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhyzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3903.2021.03.014

https://zhyzzz.cma-cmc.com.cn/EN/Y2021/V15/I03/189

References 40

1	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
2	中国医师协会器官移植医师分会，中华医学会器官移植学分会. 中国肝癌肝移植临床实践指南(2018版) [J/CD]. 中华移植杂志：电子版，2018, 12(4): 145-150.
3	Adam R, Karam V, Delvart V, et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR)[J]. J Hepatol, 2012, 57(3): 675-688.
4	Castroagudín JF, Molina-Pérez E, Ferreiro-Iglesias R, et al. Late recurrence of hepatocellular carcinoma after liver transplantation: is an active surveillance for recurrence needed？[J]. Transplant Proc, 2012, 44(6): 1565-1567.
5	Bina Possatto M, de Ataíde EC, Fazzio Escanhoela CA, et al. Factors related to hepatocellular carcinoma recurrence after liver transplantation-a Brazilian multicenter study[J]. Transplant Proc, 2017, 49(4): 863-866.
6	Mazzaferro V, Sposito C, Zhou J, et al. Metroticket 2. 0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma[J]. Gastroenterology, 2018, 154(1): 128-139.
7	周俭，肖永胜. 肝癌肝移植临床研究现状与展望[J]. 中国实用外科杂志，2020, 40(1): 37-41.
8	Vatansever S, Farajov R, Yılmaz HC, et al. Hepatitis B and hepatocellular carcinoma recurrence after living donor liver transplantation: The role of the Milan criteria[J]. Turk J Gastroenterol, 2019, 30(1): 75-80.
9	Wu L, Yang F, Lin B, et al. MicroRNA-424 expression predicts tumor recurrence in patients with hepatocellular carcinoma following liver transplantation[J]. Oncol Lett, 2018, 15(6): 9126-9132.
10	Pan Y, Chen H, Yu J. Biomarkers in hepatocellular carcinoma: current status and future perspectives[J]. Biomedicines, 2020, 8(12): 576.
11	Trevisan França de Lima L, Broszczak D, Zhang X, et al. The use of minimally invasive biomarkers for the diagnosis and prognosis of hepatocellular carcinoma[J]. Biochim Biophys Acta Rev Cancer, 2020, 1874(2): 188451.
12	Siravegna G, Marsoni S, Siena S, et al. Integrating liquid biopsies into the management of cancer[J]. Nat Rev Clin Oncol, 2017, 14(9): 531-548.
13	Kilgour E, Rothwell DG, Brady G, et al. Liquid biopsy-based biomarkers of treatment response and resistance[J]. Cancer Cell, 2020, 37(4): 485-495.
14	Xu W, Cao L, Chen L, et al. Isolation of circulating tumor cells in patients with hepatocellular carcinoma using a novel cell separation strategy[J]. Clin Cancer Res, 2011, 17(11): 3783-3793.
15	吉翔，杨艳丽，汪亚辉，等. 循环肿瘤细胞检测技术在胃癌诊治中应用的研究进展[J]. 现代肿瘤医学，2018, 26(8): 1303-1307.
16	Sun YF, Xu Y, Yang XR, et al. Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection[J]. Hepatology, 2013, 57(4): 1458-1468.
17	Wang S, Zheng Y, Liu J, et al. Analysis of circulating tumor cells in patients with hepatocellular carcinoma recurrence following liver transplantation[J]. J Investig Med, 2018, 66(5): 1-6.
18	Court CM, Hou S, Winograd P, et al. A novel multimarker assay for the phenotypic profiling of circulating tumor cells in hepatocellular carcinoma[J]. Liver Transpl, 2018, 24(7): 946-960.
19	Wan JCM, Massie C, Garcia-Corbacho J, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA[J]. Nat Rev Cancer, 2017, 17(4): 223-238.
20	García-Fernández N, Macher HC, Rubio A, et al. Detection of p53 mutations in circulating DNA of transplanted hepatocellular carcinoma patients as a biomarker of tumor recurrence[J]. Adv Exp Med Biol, 2016, 924: 25-28.
21	Krenzien F, Katou S, Papa A, et al. Increased cell-free DNA plasma concentration following liver transplantation is linked to portal hepatitis and inferior survival[J]. J Clin Med, 2020, 9(5): 1543.
22	Liao W, Yang H, Xu H, et al. Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing[J]. Oncotarget, 2016, 7(26): 40481-40490.
23	Cai ZX, Chen G, Zeng YY, et al. Circulating tumor DNA profiling reveals clonal evolution and real-time disease progression in advanced hepatocellular carcinoma[J]. Int J Cancer, 2017, 141(5): 977-985.
24	Zhang HM, Shi YX, Sun LY, et al. Hepatocellular carcinoma recurrence in living and deceased donor liver transplantation: a systematic review and meta-analysis[J]. Chin Med J (Engl), 2019, 132(13): 1599-1609.
25	Wen Y, Han J, Chen J, et al. Plasma miRNAs as early biomarkers for detecting hepatocellular carcinoma[J]. Int J Cancer, 2015, 137(7): 1679-1690.
26	Farid WR, Verhoeven CJ, de Jonge J, et al. The ins and outs of microRNAs as biomarkers in liver disease and transplantation[J]. Transpl Int, 2014, 27(12): 1222-1232.
27	Li D, Zhang J, Li J. Role of miRNA sponges in hepatocellular carcinoma[J]. Clin Chim Acta, 2020, 500: 10-19.
28	Morita K, Shirabe K, Taketomi A, et al. Relevance of microRNA-18a and microRNA-199a-5p to hepatocellular carcinoma recurrence after living donor liver transplantation[J]. Liver Transpl, 2016, 22(5): 665-676.
29	Ng KT, Lo CM, Wong N, et al. Early-phase circulating miRNAs predict tumor recurrence and survival of hepatocellular carcinoma patients after liver transplantation[J]. Oncotarget, 2016, 7(15): 19824-19839.
30	Shang W, Adzika GK, Li Y, et al. Molecular mechanisms of circular RNAs, transforming growth factor-β，and long noncoding RNAs in hepatocellular carcinoma[J]. Cancer Med, 2019, 8(15): 6684-6699.
31	Yuan D, Chen Y, Li X, et al. Long non-coding RNAs: potential biomarkers and targets for hepatocellular carcinoma therapy and diagnosis[J]. Int J Biol Sci, 2021, 17(1): 220-235.
32	Wu L, Yang Z, Zhang J, et al. Long noncoding RNA HOTTIP expression predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation[J]. Hepatobiliary Surg Nutr, 2018, 7(6): 429-439.
33	Lai MC, Yang Z, Zhou L, et al. Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation[J]. Med Oncol, 2012, 29(3): 1810-1816.
34	Agopian VG, Harlander-Locke M, Zarrinpar A, et al. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients[J]. J Am Coll Surg, 2015, 220(4): 416-427.
35	Foerster F, Hoppe-Lotichius M, Vollmar J, et al. Long-term observation of hepatocellular carcinoma recurrence after liver transplantation at a European transplantation centre[J]. United European Gastroenterol J, 2019, 7(6): 838-849.
36	Özdemir F, Baskiran A. The importance of AFP in liver transplantation for HCC[J]. J Gastrointest Cancer, 2020, 51(4): 1127-1132.
37	Nielsen MJ, Villesen IF, Gudmann NS, et al. Serum markers of type Ⅲ and Ⅳ procollagen processing predict recurrence of fibrosis in liver transplanted patients[J]. Sci Rep, 2019, 9(1): 14857.
38	Hayashi M, Yamada S, Tanabe H, et al. High serum uric acid levels could be a risk factor of hepatocellular carcinoma recurrences[J]. Nutr Cancer, 2021, 73(6): 996-1003.
39	Li Y, Xu W, Chen P, et al. Correlation analysis between preoperative serum iron level and prognosis as well as recurrence of HCC after radical resection[J]. Cancer Manag Res, 2020, 12: 31-41.
40	Cai H, Zhang Y, Meng F, et al. Preoperative serum IL6, IL8, and TNF-α may predict the recurrence of hepatocellular cancer[J]. Gastroenterol Res Pract, 2019: 6160783.

[1]	Miao Li, Lianhua Zhu, Peng Han, Bo Jiang, Xiang Fei. Evaluation of relationsip between vascular morphology and risk factors for hepatocellular carcinoma by high-frame-rate contrast-enhanced ultrasound [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(09): 911-915.
[2]	Jianmin Ding, Zhengyi Qin, Xiang Zhang, Yan Zhou, Hongyu Zhou, Yandong Wang, Xiang Jing. Contrast-enhanced ultrasound versus gadoxetic acid-enhanced magnetic resonance imaging for LI-RADS classification of focal liver lesions ≤3 cm in patients at high risk of hepatocellular carcinoma: a prospective study [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(09): 930-938.
[3]	Jie Dong, Song Yang, Hao Yang, Xiang Chen, Wanli Zhang. Relationship between hypermethylation of ACACB gene and clinicopathological factors and survival of hepatocellular carcinoma [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(06): 433-437.
[4]	Wei Huang, Qi Liu, Liuhua Chen, Chaxiang Teng, Zhejian Ou, Hanxiao Liu, Jiancong Chen, Kunsong Zhang. Identification of a pyroptosis-related lncRNA signature as a novel prognostic biomarker for hepatocellular carcinoma [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(05): 357-365.
[5]	Kunhe Li, Mengjia Kou, Liting Kuang. Risk factors and prediction model of reintubation after liver transplantation [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(05): 366-371.
[6]	Xiaowei Xing, Yuchen Liu, Bing Zhao, Minggang Wang. A research on predictive value of convolutional neural network based on preoperative abdominal CT for recurrence of incisional hernia after surgical repair [J]. Chinese Journal of Hernia and Abdominal Wall Surgery(Electronic Edition), 2023, 17(06): 677-681.
[7]	Qing Yan, Ying Liu, Feiwen Deng, Huanwei Chen. Effect of microvascular invasion on survival and prognosis of liver transplantation recipients with liver cancer [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 624-629.
[8]	Mei Liao, Hongjun Zhang, Jieyang Jin, Yan Lyu, Jie Ren. Diagnostic value of bedside contrast-enhanced ultrasound for early hepatic artery thrombosis after liver transplantation [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 630-634.
[9]	Wenhua Zhang, Cui Tao, Tiansong Hu. Clinicopathological characteristics of pedunculated hepatocellular carcinoma in different sites and its effects on postoperative intrahepatic recurrence and prognosis [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 651-655.
[10]	Binglin Li, Shaocheng Lyu, Fei Pan, Tao Jiang, Hua Fan, Jiantao Kou, Qiang He, Ren Lang. Correlation analysis between pathogenic bacteria of donor liver perfusion fluid and early infection after liver transplantation [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 656-660.
[11]	Lei Lyu, Xiao Feng, Kaiming He, Kaining Zeng, Qing Yang, Haijin Lyu, Huimin Yi, Shuhong Yi, Yang Yang, Binsheng Fu. Value of revised King's score in evaluation of live transplantation timing for children with acute liver failure due to Wilson's disease and literature review [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 661-668.
[12]	Menglong Wang. Significance of biological characteristics in liver transplantation for HCC [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(05): 490-494.
[13]	Chufeng Wang, An Jiang. Molecular diagnosis of primary liver cancer [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(05): 499-503.
[14]	Baoru Hu, Naijian Shang, Di Gao. DCE-MRI and DWI findings of advanced hepatocellular carcinoma and their correlation with prognosis after immunotherapy [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(06): 399-403.
[15]	Fengyun Wu, Xin Teng, Lianjuan Liu. Diagnostic value of high-frequency ultrasonography and enhanced magnetic resonance for primary hyperdifferentiated hepatocellular carcinoma of different diameters [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(06): 404-408.

Please choose a citation manager

Content to export